These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33850883)

  • 21. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
    Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
    Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
    Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
    Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
    Eichhorn F; Klotz LV; Kriegsmann M; Bischoff H; Schneider MA; Muley T; Kriegsmann K; Haberkorn U; Heussel CP; Savai R; Zoernig I; Jaeger D; Thomas M; Hoffmann H; Winter H; Eichhorn ME
    Lung Cancer; 2021 Mar; 153():150-157. PubMed ID: 33529989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
    Hou X; Shi X; Luo J
    Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world.
    Fang M; Hang Q; Jiang H; Cai L; Hu J; Ying H; Gu Q; Yu X; Liu J; Lai X
    Front Oncol; 2022; 12():1055610. PubMed ID: 36713546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB/IIIA Non-small Cell Lung Cancer - A Phase II trial.
    Mittal A; Malik PS; Kumar S; Saikia J; Chitikela S; Khurana S; Bharti S; Jain D; Pathy S; Thulkar S; Kumar R; Madan K; Mohan A
    Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e553-e560. PubMed ID: 34340919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.
    Shi L; Meng Q; Tong L; Li H; Dong Y; Su C; Liu Z
    Front Oncol; 2022; 12():956755. PubMed ID: 36313678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials.
    Sun L; Guo YJ; Song J; Wang YR; Zhang SL; Huang LT; Zhao JZ; Jing W; Han CB; Ma JT
    Front Oncol; 2020; 10():586596. PubMed ID: 33511076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 31. Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
    Xu Y; Ma D; Qin Y; Li S; Li J; Jiang Y; Wang M; Xu Y; Zhao J; Chen M; Cheng W; Hu K; Liu H
    Thorac Cancer; 2023 Jun; 14(17):1635-1639. PubMed ID: 37094918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer.
    Chen Y; Yan B; Xu F; Hui Z; Zhao G; Liu J; Zhang H; Zeng Z; Zhang R; Provencio M; Ren X; You J
    Transl Lung Cancer Res; 2021 May; 10(5):2193-2204. PubMed ID: 34164269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
    Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944
    [No Abstract]   [Full Text] [Related]  

  • 34. Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
    Zhai H; Li W; Jiang K; Zhi Y; Yang Z
    Cancer Manag Res; 2022; 14():515-524. PubMed ID: 35173485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
    Gao S; Li N; Gao S; Xue Q; Ying J; Wang S; Tao X; Zhao J; Mao Y; Wang B; Shao K; Lei W; Wang D; Lv F; Zhao L; Zhang F; Zhao Z; Su K; Tan F; Gao Y; Sun N; Wu D; Yu Y; Ling Y; Wang Z; Duan C; Tang W; Zhang L; He S; Wu N; Wang J; He J
    J Thorac Oncol; 2020 May; 15(5):816-826. PubMed ID: 32036071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.
    Strauss GM; Herndon JE; Sherman DD; Mathisen DJ; Carey RW; Choi NC; Rege VB; Modeas C; Green MR
    J Clin Oncol; 1992 Aug; 10(8):1237-44. PubMed ID: 1321893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.
    Zhao ZR; Yang CP; Chen S; Yu H; Lin YB; Lin YB; Qi H; Jin JT; Lian SS; Wang YZ; You JQ; Zhai WY; Long H
    Oncoimmunology; 2021; 10(1):1996000. PubMed ID: 34712513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    Forde PM; Chaft JE; Smith KN; Anagnostou V; Cottrell TR; Hellmann MD; Zahurak M; Yang SC; Jones DR; Broderick S; Battafarano RJ; Velez MJ; Rekhtman N; Olah Z; Naidoo J; Marrone KA; Verde F; Guo H; Zhang J; Caushi JX; Chan HY; Sidhom JW; Scharpf RB; White J; Gabrielson E; Wang H; Rosner GL; Rusch V; Wolchok JD; Merghoub T; Taube JM; Velculescu VE; Topalian SL; Brahmer JR; Pardoll DM
    N Engl J Med; 2018 May; 378(21):1976-1986. PubMed ID: 29658848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary experience of surgery after neoadjuvant immunotherapy combined with chemotherapy for stage-IIIB non-small cell lung cancer.
    Ding Y; Zhao X; Christopoulos P; Geraci TC; Fu Y
    J Thorac Dis; 2024 Jul; 16(7):4645-4654. PubMed ID: 39144346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.